Pharmacyclics — Q2 2010 Earnings Presentation
6 slides from Pharmacyclics's earnings presentation, Feb 11, 2010
Slide 1: Second Quarter Fiscal 2010 Conference Call Slides
@pharmacyclics Ss ox 5) A 7, y a\ N | Ce Second Quarter Fiscal 2010 Conference Call Slides Please Use Dial-in to Hear Audio Toll-free: +1-866-727-3220 International: +1-706-643-1591 Conference ID: 55218310
Slide 2: Forward-looking statements
During the course of this presentation we will make statements that constitute forward-looking statements. These statements may include operating expense projections, the initiation, timing and results of pending or future clinical trials, the actions or potential action of the FDA, the status and t
Slide 3: Pharmacyclics Development Programs
Slide 1 | Pharmacyclics De" Program BTK Inhibitors: BOLSPTESNHLICL Series compound for Autorimmune diseases — HDAC Inhibitor PCI-24781 Lymphoma —S——— PO1.24781 Sarcoma ———— nl HDAC8 = Factor VII Inhibitor CL24783 Pancreatic ————Se Cancer Motexafin Gadolinium Ot Glioblastoma i x R Pontine Glioma 1 Sp
Slide 4: Bruton's Tyrosine Kinase (Btk)
Slide 2 Bruton’s Tyrosine Kinase (Btk) Critical B and Mast Cell Signaling Kinase Novel Therapy for Inhibition of B Cell Receptor Signaling Qpharmacyclics
Slide 5: PCI-32765 clinical results
Slide 3 Pharmacyey PCI-32765: | + Evidence of drug activity in the first two cohorts evaluated (1225 -and 2.5 Response in Patient with Mantle Cell meke/day) Lymphoma = Overall response rate = 5/16 (31%) = Responses seen in Follicular, Mantle Cell CLL = MTD not reached = (Cohort 1 had no DLT; cohort
Slide 6: PCI-24781 was well tolerated
= PCI-24781 was well tolerated = Complete absence of prolonged QT intervals or other cardiac abnormalities = Preliminary clinical benefit in heavily pre-treated relapsed/refractory lymphoma patients = 1CR, 4PRand6 SDin 16 patients evaluable for response after 2 cycles = Thrombocytopenia was the most